Abstract
Allergen specific immunotherapy (ASIT) has been used for 100 years with efficacy confirmed of Subcutaneous Allergen Immunotherapy (SCIT) seen in numerous double-blind placebo controlled studies but recent evidence notes efficacy of sublingual immunotherapy (SLIT) which may be better tolerated than SCIT. This study assesses the efficacy and tolerability of both SCIT and SLIT in clinical practice.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
